SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VISX
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: pappy who wrote (522)4/23/1998 2:24:00 AM
From: Jim Mac  Read Replies (1) of 1754
 
Hey, believe me, I wish I'D bought LCAV below $1. But I also wish I'd bought YHOO at $10 long ago...and Iomega before people went nuts for that one too.

I can't help it if LCAV is overpriced now. That should be clear to anyone. The small float has been largely responsible for the run, which can't be sustained unless a mania develops.

I like LCAV as a company, but LZRCF is even better, and LVCI is the best deal, partly because LVCI is the lowest-risk, LCAV is the highest-risk. LVCI can make $1.00-$1.50 fully-taxed in calendar 1999 (with hyperopia). Not true with LZRCF, and LCAV isn't likely to earn more than $0.25 fully-taxed in 1999.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News